-
1
-
-
84876369710
-
Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT Trials compared to the general population
-
Rodger AJ, Lodwick R, Schecter M, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT Trials compared to the general population. AIDS. 2013;27(6):973-997.
-
(2013)
AIDS
, vol.27
, Issue.6
, pp. 973-997
-
-
Rodger, A.J.1
Lodwick, R.2
Schecter, M.3
-
2
-
-
84940530289
-
Initiation of antiretroviral therapy in early asymptomatic HIV infection
-
Lundgren JA, Babiker AG, Gordin F, et al; INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807.
-
(2015)
N Engl J Med
, vol.373
, Issue.9
, pp. 795-807
-
-
Lundgren, J.A.1
Babiker, A.G.2
Gordin, F.3
-
3
-
-
84954209401
-
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): Effectiveness results from the pilot phase of a pragmatic open-label randomised trial
-
McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53-60.
-
(2016)
Lancet
, vol.387
, Issue.10013
, pp. 53-60
-
-
McCormack, S.1
Dunn, D.T.2
Desai, M.3
-
4
-
-
84948822953
-
On-demand pre-exposure prophylaxis in men at high risk for HIV-1 infection
-
Molina JM, Capitant C, Spire B, et al; ANRS IPERGAY Study Group. On-demand pre-exposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237-2246.
-
(2015)
N Engl J Med
, vol.373
, Issue.23
, pp. 2237-2246
-
-
Molina, J.M.1
Capitant, C.2
Spire, B.3
-
5
-
-
78650549662
-
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men
-
Grant RM, Lama JR, Anderson PL, et al; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-2599.
-
(2010)
N Engl J Med
, vol.363
, pp. 2587-2599
-
-
Grant, R.M.1
Lama, J.R.2
Anderson, P.L.3
-
6
-
-
84864505868
-
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women
-
Baeten JM, Donnell D, Ndase P, et al; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399-410.
-
(2012)
N Engl J Med
, vol.367
, Issue.5
, pp. 399-410
-
-
Baeten, J.M.1
Donnell, D.2
Ndase, P.3
-
7
-
-
84864527306
-
Antiretroviral pre-exposure prophylaxis for heterosexual HIV transmission in Botswana
-
Thigpen MC, Kebaabetswe PM, Paxton LA, et al; TDF2 Study Group. Antiretroviral pre-exposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423-434.
-
(2012)
N Engl J Med
, vol.367
, Issue.5
, pp. 423-434
-
-
Thigpen, M.C.1
Kebaabetswe, P.M.2
Paxton, L.A.3
-
8
-
-
84864507852
-
Pre-exposure prophylaxis for HIV infection among African women
-
Van Damme L, Corneli A, Ahmed K, et al; FEM-PrEP Study Group. Pre-exposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411-422.
-
(2012)
N Engl J Med
, vol.367
, Issue.5
, pp. 411-422
-
-
Van Damme, L.1
Corneli, A.2
Ahmed, K.3
-
9
-
-
84966586679
-
Single versus multiple-tablet HIV regimens: Adherence and hospitalization risk
-
Sutton SS, Hardin JW, Bramley TJ, D’Souza AO, Bennett CL. Single versus multiple-tablet HIV regimens: adherence and hospitalization risk. Am J Manag Care. 2016;22(4):242-248.
-
(2016)
Am J Manag Care
, vol.22
, Issue.4
, pp. 242-248
-
-
Sutton, S.S.1
Hardin, J.W.2
Bramley, T.J.3
D’Souza, A.O.4
Bennett, C.L.5
-
10
-
-
84947938552
-
Meta-analysis of studies comparing single and multi-tablet fixed dose combination HIV treatment regimens
-
Clay PG, Nag S, Graham CM, Narayanan S. Meta-analysis of studies comparing single and multi-tablet fixed dose combination HIV treatment regimens. Medicine (Baltimore). 2015;94(42):e1677.
-
(2015)
Medicine (Baltimore)
, vol.94
, Issue.42
-
-
Clay, P.G.1
Nag, S.2
Graham, C.M.3
Narayanan, S.4
-
11
-
-
84919458152
-
Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviralnaive adults infected with HIV-1: 96 week results from the NEAT001/ ANRS143 randomised non-inferiority trial
-
Raffi F, Babiker AG, Richert L, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviralnaive adults infected with HIV-1: 96 week results from the NEAT001/ ANRS143 randomised non-inferiority trial. Lancet. 2014;384(9958): 1942-1951.
-
(2014)
Lancet
, vol.384
, Issue.9958
, pp. 1942-1951
-
-
Raffi, F.1
Babiker, A.G.2
Richert, L.3
-
12
-
-
80055028058
-
ACTG A5262 Team. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)
-
Taiwo B, Zheng L, Gallien S, et al; ACTG A5262 Team. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS. 2011;25(17):2113-2122.
-
(2011)
AIDS
, vol.25
, Issue.17
, pp. 2113-2122
-
-
Taiwo, B.1
Zheng, L.2
Gallien, S.3
-
13
-
-
84959203087
-
Dolutegravirlamivudine as initial therapy in HIV-infected, ARV naive patients: First results of the PADDLE trial
-
October 21-24, Barcelona, Spain
-
Figueroa M, Sued O, Patterson P, Gun A, Rolon M, Cahn P. Dolutegravirlamivudine as initial therapy in HIV-infected, ARV naive patients: first results of the PADDLE trial. In: 15th European AIDS Conference. October 21-24, 2015. Barcelona, Spain.
-
(2015)
15Th European AIDS Conference
-
-
Figueroa, M.1
Sued, O.2
Patterson, P.3
Gun, A.4
Rolon, M.5
Cahn, P.6
-
14
-
-
84962513459
-
The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: A randomised controlled trial of a protease inhibitor monotherapy strategy for longterm management of human immunodeficiency virus infection
-
Paton NI, Stohr W, Oddershede L, et al. The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for longterm management of human immunodeficiency virus infection. Health Technol Assess. 2016;20(21):1-158.
-
(2016)
Health Technol Assess
, vol.20
, Issue.21
, pp. 1-158
-
-
Paton, N.I.1
Stohr, W.2
Oddershede, L.3
-
15
-
-
84898016347
-
Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis
-
Solomon MM, Lama JR, Glidden DV, et al. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS. 2014;28(6):851-859.
-
(2014)
AIDS
, vol.28
, Issue.6
, pp. 851-859
-
-
Solomon, M.M.1
Lama, J.R.2
Glidden, D.V.3
-
17
-
-
84937215233
-
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: Two randomised, double-blind, phase 3, non-inferiority trials
-
Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385(9987): 2606-2615.
-
(2015)
Lancet
, vol.385
, Issue.9987
, pp. 2606-2615
-
-
Sax, P.E.1
Wohl, D.2
Yin, M.T.3
-
18
-
-
84857772222
-
Long-acting antipsychotic medications
-
Baweja R, Sedky K, Lippman S. Long-acting antipsychotic medications. Curr Drug Targets. 2012;13(4):555-560.
-
(2012)
Curr Drug Targets
, vol.13
, Issue.4
, pp. 555-560
-
-
Baweja, R.1
Sedky, K.2
Lippman, S.3
-
19
-
-
40649085987
-
Hormonal contraceptive discontinuation patterns according to formulation: Investigation of associations in an administrative claims database
-
Murphy P, Brixner D. Hormonal contraceptive discontinuation patterns according to formulation: investigation of associations in an administrative claims database. Contraception. 2008;77(4):257-263.
-
(2008)
Contraception
, vol.77
, Issue.4
, pp. 257-263
-
-
Murphy, P.1
Brixner, D.2
-
20
-
-
34548679894
-
Assessing regional differences in contraceptive disconti-nuation, failure and switching in Brazil
-
Leite IC, Gupta N. Assessing regional differences in contraceptive disconti-nuation, failure and switching in Brazil. Reprod Health. 2007;4:6.
-
(2007)
Reprod Health
, vol.4
, pp. 6
-
-
Leite, I.C.1
Gupta, N.2
-
21
-
-
84992385561
-
Understanding pain and anxiety experienced around long-acting injectable PrEP
-
February, Boston, Massachusetts Abstract number 881
-
Meyers K, Rodriguez K, Markowitz M, Golub SA. Understanding pain and anxiety experienced around long-acting injectable PrEP. In: CROI, February 2016. Boston, Massachusetts Abstract number 881.
-
(2016)
CROI
-
-
Meyers, K.1
Rodriguez, K.2
Markowitz, M.3
Golub, S.A.4
-
22
-
-
84886473877
-
Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor
-
Spreen W, Min S, Ford SL, et al. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials. 2013;14(5):192-203.
-
(2013)
HIV Clin Trials
, vol.14
, Issue.5
, pp. 192-203
-
-
Spreen, W.1
Min, S.2
Ford, S.L.3
-
23
-
-
84992313756
-
-
webpage on the Internet, updated on eMC July 1, Accessed June 8
-
EMC [webpage on the Internet]. Isentress 400 mg Film-coated Tablets-summary of product characteristics (SPC). [updated on eMC July 1, 2015]. Available from: http://www.medicines.org.uk/emc/ medicine/20484/SPC/. Accessed June 8, 2016.
-
(2015)
Isentress 400 Mg Film-Coated Tablets-Summary of Product Characteristics (SPC)
-
-
-
25
-
-
84871869890
-
-
Department of Health and Human Services
-
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. Available from: http://www.aidsinfo.nih.gov/ContentFiles/Adultand AdolescentGL.pdf. Accessed 8 June 2016.
-
Guidelines for the Use of Antiretroviral Agents in Hiv-1-Infected Adults and Adolescents
-
-
-
26
-
-
84992357039
-
-
European AIDS Clinical Society Guidelines Version 8.0 English October 2015, Accessed 8 June
-
EACS. European AIDS Clinical Society Guidelines Version 8.0 English October 2015. Available from: http://www.eacsociety.org/files/ guidelines_8.0-english.pdf. Accessed 8 June 2016.
-
(2016)
-
-
-
27
-
-
84904568743
-
Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel
-
Gunthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014;312(4):410-425.
-
(2014)
JAMA
, vol.312
, Issue.4
, pp. 410-425
-
-
Gunthard, H.F.1
Aberg, J.A.2
Eron, J.J.3
-
29
-
-
0035876041
-
Non-adherence to highly active antiretroviral therapy predicts progression to AIDS
-
Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181-1183.
-
(2001)
AIDS
, vol.15
, Issue.9
, pp. 1181-1183
-
-
Bangsberg, D.R.1
Perry, S.2
Charlebois, E.D.3
-
30
-
-
0036570904
-
Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients
-
Garcia de Ololla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr. 2002;30(1):105-110.
-
(2002)
J Acquir Immune Defic Syndr
, vol.30
, Issue.1
, pp. 105-110
-
-
Garcia De Ololla, P.1
Knobel, H.2
Carmona, A.3
Guelar, A.4
Lopez-Colomes, J.L.5
Cayla, J.A.6
-
31
-
-
84923701359
-
GSK1265744 demonstrates robust in vitro activity against various clades of HIV-1
-
Karmon SL, Mohri H, Spreen W, Markowitz M. GSK1265744 demonstrates robust in vitro activity against various clades of HIV-1. J Acquir Immune Defic Syndr. 2015;68(3):e39-e41.
-
(2015)
J Acquir Immune Defic Syndr
, vol.68
, Issue.3
, pp. e39-e41
-
-
Karmon, S.L.1
Mohri, H.2
Spreen, W.3
Markowitz, M.4
-
32
-
-
84920189964
-
Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection
-
Yoshinaga T, Kobayashi M, Seki T, et al. Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection. Antimicrob Agents Chemother. 2015;59(1):397-406.
-
(2015)
Antimicrob Agents Chemother
, vol.59
, Issue.1
, pp. 397-406
-
-
Yoshinaga, T.1
Kobayashi, M.2
Seki, T.3
-
33
-
-
84925557632
-
GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects
-
Spreen W, Ford SL, Chen S, et al. GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects. J Acquir Immune Defic Syndr. 2014;67(5):481-486.
-
(2014)
J Acquir Immune Defic Syndr
, vol.67
, Issue.5
, pp. 481-486
-
-
Spreen, W.1
Ford, S.L.2
Chen, S.3
-
34
-
-
84921020451
-
Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults
-
Spreen W, Williams P, Margolis D, et al. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults. J Acquir Immune Defic Syndr. 2014;67(5):487-492.
-
(2014)
J Acquir Immune Defic Syndr
, vol.67
, Issue.5
, pp. 487-492
-
-
Spreen, W.1
Williams, P.2
Margolis, D.3
-
35
-
-
84943154337
-
Formulation and pharmacology of long-acting cabotegravir
-
Trezza L, Ford SL, Spreen W, Pan R, Piscitelli S. Formulation and pharmacology of long-acting cabotegravir. Curr Opin HIV AIDS. 2015;10(4): 239-245.
-
(2015)
Curr Opin HIV AIDS
, vol.10
, Issue.4
, pp. 239-245
-
-
Trezza, L.1
Ford, S.L.2
Spreen, W.3
Pan, R.4
Piscitelli, S.5
-
36
-
-
84987791972
-
-
ViiV Healthcare Ltd, Accessed July 1
-
ViiV Healthcare Ltd. Dolutegravir Summary of Product Characteristics. ViiV Healthcare Ltd; 2015. Available from: https://www.medicines.org.uk/emc/medicine/28545isdolutegravirspc. Accessed July 1, 2016.
-
(2015)
Dolutegravir Summary of Product Characteristics
-
-
-
37
-
-
84958121340
-
Drug interaction profile of the HIV integrase inhibitor cabotegravir: Assessment from in vitro studies and a clinical investigation with midazolam
-
Reese MJ, Bowers GD, Humphreys JE, et al. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica. 2016;46(5):445-456.
-
(2016)
Xenobiotica
, vol.46
, Issue.5
, pp. 445-456
-
-
Reese, M.J.1
Bowers, G.D.2
Humphreys, J.E.3
-
38
-
-
84872050289
-
Effects of etravirine on the pharmacokinetics of the integrase inhibitor S/GSK 1265744
-
Ford SL, Gould E, Chen S, et al. Effects of etravirine on the pharmacokinetics of the integrase inhibitor S/GSK 1265744. Antimicrob Agents Chemother. 2013;57(1):277-280.
-
(2013)
Antimicrob Agents Chemother
, vol.57
, Issue.1
, pp. 277-280
-
-
Ford, S.L.1
Gould, E.2
Chen, S.3
-
39
-
-
84992353740
-
-
Phase 1, Single-Center, Open-Label, Fixed Sequence Cross-Over Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects, Accessed July 1
-
Glaxo Smith Kline PLC. Phase 1, Single-Center, Open-Label, Fixed Sequence Cross-Over Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects. Available from: http://www.gsk-clinicalstudyregister.com/files2/gsk-117010-clinical-study-result-summary.pdf. Accessed July 1, 2016.
-
(2016)
-
-
Glaxo Smith Kline, P.L.C.1
-
41
-
-
84885934539
-
Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK 1265744
-
Ford SL, Gould E, Chen S, et al. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK 1265744. Antimicrob Agents Chemother. 2013;57(11):5472-5477.
-
(2013)
Antimicrob Agents Chemother
, vol.57
, Issue.11
, pp. 5472-5477
-
-
Ford, S.L.1
Gould, E.2
Chen, S.3
-
42
-
-
84921044609
-
The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge
-
Radzio J, Spreen W, Yueh YL, et al. The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge. Sci Transl Med. 2015;7(270):270ra5.
-
(2015)
Sci Transl Med
, vol.7
, Issue.270
-
-
Radzio, J.1
Spreen, W.2
Yueh, Y.L.3
-
43
-
-
85017409155
-
Eclair: Phase 2A safety and PK study of Cabotegravir LA in HIV-uninfected men
-
February, Boston, Massachusetts Abstract number 106
-
Markowitz M, Frank I, Grant R, et al. Eclair: phase 2A safety and PK study of Cabotegravir LA in HIV-uninfected men. In: CROI, February 2016. Boston, Massachusetts Abstract number 106.
-
(2016)
CROI
-
-
Markowitz, M.1
Frank, I.2
Grant, R.3
-
44
-
-
84896769378
-
Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus
-
Andrews CD, Spreen WR, Mohri H, et al. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science. 2014;343(6175):1151-1154.
-
(2014)
Science
, vol.343
, Issue.6175
, pp. 1151-1154
-
-
Andrews, C.D.1
Spreen, W.R.2
Mohri, H.3
-
45
-
-
84992385550
-
-
Clinicaltrials.gov. Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women Who Have Sex With Men, Accessed July 1
-
National Institutes of Health. Clinicaltrials.gov. Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women Who Have Sex With Men. Available from: https://clinicaltrials.gov/show/NCT02720094. Accessed July 1, 2016.
-
(2016)
-
-
-
46
-
-
19944428117
-
Multiple vaginal exposures to low doses of R5 simian-human immuno-deficiency virus: Strategy to study HIV preclinical interventions in nonhuman primates
-
Otten RA, Adams DR, Kim CN, et al. Multiple vaginal exposures to low doses of R5 simian-human immuno-deficiency virus: strategy to study HIV preclinical interventions in nonhuman primates. J Infect Dis. 2005;191(2):164-173.
-
(2005)
J Infect Dis
, vol.191
, Issue.2
, pp. 164-173
-
-
Otten, R.A.1
Adams, D.R.2
Kim, C.N.3
-
47
-
-
84870748389
-
Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen
-
Radzio J, Aung W, Holder A, et al. Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen. PLoS One. 2012;7(12):e50632.
-
(2012)
Plos One
, vol.7
, Issue.12
-
-
Radzio, J.1
Aung, W.2
Holder, A.3
-
48
-
-
0023033053
-
Man versus beast: Pharmacokinetic scaling in mammals
-
Mordenti J. Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci. 1986;75(11):1028-1040.
-
(1986)
J Pharm Sci
, vol.75
, Issue.11
, pp. 1028-1040
-
-
Mordenti, J.1
-
49
-
-
84902294966
-
Physiologic doses of depot-medroxypro-gesterone acetate do not increase acute plasma simian HIV viremia or mucosal virus shedding in pigtail macaques
-
Radzio J, Hanley K, Mitchell J, et al. Physiologic doses of depot-medroxypro-gesterone acetate do not increase acute plasma simian HIV viremia or mucosal virus shedding in pigtail macaques. AIDS. 2014; 28(10):1431-1439.
-
(2014)
AIDS
, vol.28
, Issue.10
, pp. 1431-1439
-
-
Radzio, J.1
Hanley, K.2
Mitchell, J.3
-
50
-
-
84992391209
-
Cabotegravir long-acting injection protects macaques against intravenous challenge
-
February, Boston, Massachusetts Abstract number
-
Andrews CD, St Bernard L, Poon A, et al. Cabotegravir long-acting injection protects macaques against intravenous challenge. In: CROI, February 2016. Boston, Massachusetts Abstract number 105.
-
(2016)
CROI
, pp. 105
-
-
Andrews, C.D.1
St Bernard, L.2
Poon, A.3
-
51
-
-
85017409155
-
ECLAIR: Phase 2A safety and PK study of Cabotegravir LA in HIV-uninfected men
-
February, Boston, Massachusetts Abstract number
-
Markowitz M, Frank I, Grant R, et al. ECLAIR: phase 2A safety and PK study of Cabotegravir LA in HIV-uninfected men. In: CROI, February 2016. Boston, Massachusetts Abstract number 106.
-
(2016)
CROI
, pp. 106
-
-
Markowitz, M.1
Frank, I.2
Grant, R.3
-
52
-
-
84992313745
-
-
webpage on the Internet, GSK1265744, in HIV-uninfected men and women. Study protocol final version 2.0. IND # 122744. DAIDS Document ID: 11964, Accessed June 21
-
HPTN 077 [webpage on the Internet]. A Phase IIa study to evaluate the safety, tolerability and pharma-cokinetics of the investigational injectable HIV integrase inhibitor, GSK1265744, in HIV-uninfected men and women. Study protocol final version 2.0. IND # 122744. DAIDS Document ID: 11964. Available from: https://www.hptn.org/research/studies/153. Accessed June 21, 2016.
-
(2016)
A Phase Iia Study to Evaluate the Safety, Tolerability and Pharma-Cokinetics of the Investigational Injectable HIV Integrase Inhibitor
-
-
-
53
-
-
84942191100
-
LAI116482 Study Team. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): A randomised, phase 2b, dose-ranging trial
-
Margolis DA, Brinson CC, Smith GH, et al; LAI116482 Study Team. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis. 2015;15(10): 1145-1155.
-
(2015)
Lancet Infect Dis
, vol.15
, Issue.10
, pp. 1145-1155
-
-
Margolis, D.A.1
Brinson, C.C.2
Smith, G.H.3
-
54
-
-
84879874721
-
Dolutegravir in antiretroviralnaive adults with HIV-1: 96 week results from a randomized doseranging study
-
Stellbrink HJ, Reynes J, Lazzarin A, et al. Dolutegravir in antiretroviralnaive adults with HIV-1: 96 week results from a randomized doseranging study. AIDS. 2013;27(11):1771-1778.
-
(2013)
AIDS
, vol.27
, Issue.11
, pp. 1771-1778
-
-
Stellbrink, H.J.1
Reynes, J.2
Lazzarin, A.3
-
55
-
-
84887052771
-
Dolutegravir plus abacavirlamivudine for the treatment of HIV-1 infection
-
Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavirlamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807-1818.
-
(2013)
N Engl J Med
, vol.369
, Issue.19
, pp. 1807-1818
-
-
Walmsley, S.L.1
Antela, A.2
Clumeck, N.3
-
56
-
-
84988948359
-
Cabotegravir + Rilpivirine as long acting maintenance therapy: LATTE-2 week 32 results
-
February, Boston, Massachusetts. Abstract Number: 31LB
-
Margolis DA, Gonazalez-Garcia J, Stellbrink HJ, et al. Cabotegravir + Rilpivirine as long acting maintenance therapy: LATTE-2 week 32 results. In: CROI, February 2016 Boston, Massachusetts. Abstract Number: 31LB.
-
(2016)
CROI
-
-
Margolis, D.A.1
Gonazalez-Garcia, J.2
Stellbrink, H.J.3
-
57
-
-
84998571678
-
Tolerability and acceptability of cabotegravir LA injection: Results from ECLAIR study
-
February, Boston, Massachusetts Abstract number 471
-
Murray M, Markowitz M, Frank I, et al. Tolerability and acceptability of cabotegravir LA injection: results from ECLAIR study. In: CROI, February 2016. Boston, Massachusetts Abstract number 471.
-
(2016)
CROI
-
-
Murray, M.1
Markowitz, M.2
Frank, I.3
|